| Item |
Information |
|
Drug Groups
|
approved |
|
Description
|
Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy. |
| Indication |
Used in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy. |
| Pharmacology |
Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. |
| Affected Organisms |
| • |
Humans and other mammals |
|
| Biotransformation |
Hepatic, to two metabolites via N-dealylation and hydroxylation. |
| Absorption |
85% following oral administration. |
| Half Life |
18 days |
| Protein Binding |
99% bound to plasma proteins |
| External Links |
|